1ans DGR, Huson SM, Donnai D, et al: A clinical study of type 2 neurofibromatosis. Q. J. Med. 1992;304:603-618.
2Trofatter JA, MacCollin M, Hutter Jl, et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72:791～800.
3Rouleau GA, Merel P, Lutchman M, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993; 63:515～521.
4Crepaldi T, Gautreau A, Comoglio PM, et al: Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 1997; 138: 423～434.
5Pearson MA, Reczek D, Bretscher A, et al: Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 2000;101:259～270.
6Sherman L, Xu H-M, Geist RT, et al: Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene. 1997;15:2505～2509.
7Haase V, Trofatter J, MacCollin M, et al: The murine NF2 homologue encodes a highly conserved merlin protein with alternative forms. Hum Mol Genet. 1994;3:407～411.
8Tsukita S, Yonemura S, Tsukita S, et al: ERM family: from cytoskeleton to signal transduction. Curr. Opin. Cell Biol. 1997;9:70～75.
9Scoles DR., Huynh DP, Chen MS, et al: The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum. Mol. Genet. 2000;9:1567～1574.
10Sherman L, Sleeman J, Herrlich P, et al: Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr. Opin. Cell Biol. 1994;6:726～733.
